Rapid Urine Test Detects Legionella
By LabMedica International staff writers Posted on 27 Mar 2013 |

Image: The TRU Legionella assay (Photo courtesy of Meridian Bioscience).

Image: The Binax NOW urinary antigen test (Photo courtesy of Alere).
The test is a single use capture immunoassay to detect Legionella pneumophila serogroup 1 in human urine specimens and consists of a conjugate tube, a test strip, and sample diluent/negative control.
Scientists at The Regional Laboratory of Public Health, (Haarlem, The Netherlands) evaluated an immunochromatographic urine antigen test (ICT) on 213 frozen urine samples that were unconcentrated from a sample collection of patients with and without LD that were collected between 2000 and 2011. They compared the results of the assay with another commercial test.
The test, called the TRU Legionella assay, has a conjugate tube containing a lyophilized bead of colloidal gold-linked polyclonal antibody to L. pneumophila serogroup 1 detector antibody. The test strip carries a nitrocellulose membrane with dried capture antibodies placed at a designated test line for Legionella. The test strip holder caps the conjugate tube during testing and subsequent disposal to reduce exposure to potential pathogens.
The sensitivity and specificity of the Meridian TRU Legionella assay (Meridian Bioscience; Cincinnati, OH, USA) were compared with the test results obtained by the widely used ICT assay, the Binax NOW urinary antigen test (Binax; Portland, ME, USA). Both antigen tests were performed simultaneously and the results were interpreted at 15 minutes for the Binax NOW test and at 20 minutes for Meridian TRU Legionella strip. To investigate if a prolonged incubation time would affect the sensitivity, the samples were also read at 30, 45, and 60 minutes of incubation.
The sensitivity was estimated as 73.3% for the Meridian TRU Legionella test and 76.3% for the Binax NOW urine antigen test. The specificity was 100% for both assays. There were five samples, which were positive in the Binax NOW and negative in the Meridian TRU Legionella test, and those five samples were all positive in an enzyme immunoassay-control test. After a prolonged incubation, the same five samples were also positive in the Meridian TRU Legionella test. When the tests were re-examined after 60 minutes of incubation the sensitivity of the Meridian TRU Legionella test increased to 80.6 % and to 81.3 % for the Binax NOW urine antigen test.
The authors concluded that both assays evaluated have similar performance characteristics and are suitable for the detection of L. pneumophila antigen in urine from patients suspected of having LD. As the prolongation of incubation does not affect the specificity, it is recommended that an incubation time longer than that recommended by the manufacturer be used routinely. The study was published in the March 2013 issue of the European Journal of Clinical Microbiology & Infectious Diseases.
Related Links:
Dutch Regional Laboratory of Public Health
Meridian Bioscience
Binax
Scientists at The Regional Laboratory of Public Health, (Haarlem, The Netherlands) evaluated an immunochromatographic urine antigen test (ICT) on 213 frozen urine samples that were unconcentrated from a sample collection of patients with and without LD that were collected between 2000 and 2011. They compared the results of the assay with another commercial test.
The test, called the TRU Legionella assay, has a conjugate tube containing a lyophilized bead of colloidal gold-linked polyclonal antibody to L. pneumophila serogroup 1 detector antibody. The test strip carries a nitrocellulose membrane with dried capture antibodies placed at a designated test line for Legionella. The test strip holder caps the conjugate tube during testing and subsequent disposal to reduce exposure to potential pathogens.
The sensitivity and specificity of the Meridian TRU Legionella assay (Meridian Bioscience; Cincinnati, OH, USA) were compared with the test results obtained by the widely used ICT assay, the Binax NOW urinary antigen test (Binax; Portland, ME, USA). Both antigen tests were performed simultaneously and the results were interpreted at 15 minutes for the Binax NOW test and at 20 minutes for Meridian TRU Legionella strip. To investigate if a prolonged incubation time would affect the sensitivity, the samples were also read at 30, 45, and 60 minutes of incubation.
The sensitivity was estimated as 73.3% for the Meridian TRU Legionella test and 76.3% for the Binax NOW urine antigen test. The specificity was 100% for both assays. There were five samples, which were positive in the Binax NOW and negative in the Meridian TRU Legionella test, and those five samples were all positive in an enzyme immunoassay-control test. After a prolonged incubation, the same five samples were also positive in the Meridian TRU Legionella test. When the tests were re-examined after 60 minutes of incubation the sensitivity of the Meridian TRU Legionella test increased to 80.6 % and to 81.3 % for the Binax NOW urine antigen test.
The authors concluded that both assays evaluated have similar performance characteristics and are suitable for the detection of L. pneumophila antigen in urine from patients suspected of having LD. As the prolongation of incubation does not affect the specificity, it is recommended that an incubation time longer than that recommended by the manufacturer be used routinely. The study was published in the March 2013 issue of the European Journal of Clinical Microbiology & Infectious Diseases.
Related Links:
Dutch Regional Laboratory of Public Health
Meridian Bioscience
Binax
Latest Microbiology News
- New Blood Test Detects Up to Five Infectious Diseases at POC
- Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
- New Test Diagnoses Bacterial Meningitis Quickly and Accurately
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreMolecular Diagnostics
view channel
POC Oral Swab Test to Increase Chances of Pregnancy in IVF
Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more
Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections
Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more